期刊文献+

符合线路SPECT ^(18)F-FDG显像诊断结外淋巴瘤 被引量:5

Application of SPECT ^(18)F-FDG imaging with coincidence in diagnosis of extranodal lymphoma
下载PDF
导出
摘要 目的 探讨符合线路SPECT诊断结外淋巴瘤中的临床应用价值。方法 使用美国ADAC公司生产的VertexPlusEPICMCD/ACSPECT/PET ,对 18例术前或术后的NHL患者进行18F FDG代谢显像。对其中 9例原发和 /或继发结外NHL的显像结果进行定性和半定量分析 ,并与同期常规影像 (超声、CT)比较 ,结果经组织病理学证实。结果 符合线路SPECT 18F FDG代谢显像发现 9例结外NHL有 11个18F FDG摄取异常增高病灶 ,其对结外NHL病灶探测的敏感性、特异性和准确性分别为 85 %(11/ 13 )、10 0 %(2 / 2 )、86.7%(13 / 15 )。CT发现 6个病灶 ,其敏感性、特异性和准确性分别为 3 0 .8%(4 / 13 )、10 0 %(2 / 2 )、40 %(6/ 15 )。结论 符合线路SPECT 18F FDG代谢显像对结外淋巴瘤的诊断不失为一种有用的辅助检查方法 ,具有重要的临床价值。 Objective To investigate the clinical application value of SPECT with coincidence in the diagnosis of extranodal lymphoma. Methods Eighteen patients with NHL were performed with 18 F -FDG metabolic imaging pre- and postoperation using a Vertex Plus EPIC MCD/AC from ADAC company. The findings of 18 F -FDG metabolic images were analyzed in qualitative and semi-quantitative ways for nine of them who had an extranodal NHL located in primary and/or secondary organs determined histopathologically. 18 F -FDG images were compared with synchronous routine images such as ultrasonography and CT. Results There were 13 lesions in 9 patients with extranodal NHL in this study. SPECT with coincidence found 11 lesions of marked increasing of FDG uptake. The diagnostic sensitivity,specificity and accuracy of extranodal NHL were 85%,100% and 86.7%. CT found 6 lesions only. The sensitivity,specificity and accuracy of CT were 30.8%,100% and 40%,respectively. Conclusion 18 F -FDG metabolic imaging of SPECT with coincidence plays an important role in the diagnosis of patients with extranodal NHL,which has a clinical application significance.
出处 《中国医学影像技术》 CSCD 2004年第4期626-629,共4页 Chinese Journal of Medical Imaging Technology
关键词 ^18F-FDG 符合线路SPECT 代谢显像 淋巴瘤 18F-FDG SPECT with coincidence Metabolic imaging Lymphoma
  • 相关文献

参考文献19

  • 1Schoder H, Meta J, Yap C, et al. Effect of whole-body (18)F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma[J]. J Nucl Med, 2001, 42(8): 1139-1143.
  • 2Klose T, Leidl R, Buchmann I, et al. Primary staging of lymphomas: cost-effectiveness of FDG-PET versus computed tomography[J]. Eur J Nucl Med, 2000, 27(10):1457-1464.
  • 3Lowe VJ, Wiseman GA. Assessment of lymphoma therapy using (18)F-FDG PET[J]. J Nucl Med, 2002, 43(8): 1028-1030.
  • 4Kostakoglu L, Coleman M, Leonard P, et al. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease [J]. J Nucl Med, 2002, 43(8): 1018-1027.
  • 5Sam W, Levine S, Farner C, et al. Detection of small bowel involvement by mantle cell lymphoma on F-18 FDG positron emission tomography[J]. Clin Nucl Med, 2002, 27(5): 330-333.
  • 6Wang RF, Zhang XM, Cen XN. Clinical staging and evaluation of therapeutic effectives of malignant lymphoma with glucose metabolic imaging. Chin J Hematol,2002,23(10): 522-523.王荣福,张秀梅,岑溪南.葡萄糖代谢显像对恶性淋
  • 7Moog F, Bangerter M, Diedrichs C, et al. Extranodal malignant lymphoma: detection with FDG PET versus CT [J]. Radiology, 1998, 206(2):475-481.
  • 8Bangerter M, Kotzerke J. Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest [J]. Acta Oncol, 1999, 38(6): 799-804.
  • 9Stumpe KDM, Urbinelli M, Steinert C, et al. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: Effectiveness and comparison with computed tomography [J]. Eur J Nucl Med, 1998, 25(7): 721-728.
  • 10Jerusalem G, Warland V, Najjar F, et al. Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma [J]. Nucl Med Commun, 1999, 20(1): 13-20.

二级参考文献1

共引文献27

同被引文献62

  • 1王荣福.核医学分子功能成像和靶向治疗在淋巴瘤中临床应用进展[J].肿瘤学杂志,2009,15(9):861-865. 被引量:3
  • 2莫祥兰,浣孝强.MALT淋巴瘤分子遗传学特点[J].四川肿瘤防治,2005,18(1):51-53. 被引量:1
  • 3姚忠强,杨洪文,肖国有.^(18)F-FDG SPECT/CT同机融合显像在肿瘤诊断中的应用[J].广西医学,2006,28(2):204-205. 被引量:1
  • 4张群,陈龙邦,王靖华,朱虹,耿怀成,褚晓源,管晓翔,宋海珠,金洁.正电子发射型计算机断层扫描/计算机体层扫描在恶性淋巴瘤临床分期中的初步应用[J].医学研究生学报,2007,20(4):394-397. 被引量:13
  • 5Jerusalem G, Hustinx R, Beguin Y, et al. Evaluation of therapy for lymphoma. Semin Nucl Med, 2005,35(3) : 186-196.
  • 6Even Sapir E, Lievshitz G, Perry C, et al. Fluorine-18 fluorodeoxyglucose PET/CT patterns of extranodal involvement in patients with non-Hodgkin lymphoma and Hodgkin' s disease. Radiol Clin North Am, 2007,45(4):697-709.
  • 7Kazama T, Faria SC, Varavithya V, et al. FDG PET in the evaluation of treatmnt for lymphoma: clinical usefulness and pitfalls. Radiographics, 2005,25( 1 ) : 191-207.
  • 8Zijlstra JM, Lindauer-van der Werf G, Hoekstra OS, et al. ^18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. Haematologica, 2006,91(4) :522-529.
  • 9Rhodes MM, Delbeke D, Whitlock JA, et al. Utility of FDGPET/CT in follow-up of children treated for Hodgkin and nonHodgkin lymphoma. J Pediatr Hematol Oncol, 2006, 28 ( 5 ) : 300- 306.
  • 10Coleman M, Kostakoglu L. Early 18F labeled fluoro-2-deoxy-D- glucose positron emission tomography scanning in the lymphomas-changing the paradigms of treatments. Cancer, 2006, 107 (7) : 1425-1428.

引证文献5

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部